An expert witness testifying on behalf of a plaintiff in an Actos bladder cancer lawsuit has alleged that manufacturer Takeda Pharmaceuticals intentionally hid bladder cancer risks. University of Georgia toxicologist Randall Tackett made the testimony on behalf of Frances Wisniewski, who says she developed bladder cancer after taking Actos to treat her type 2 diabetes.
Tackett pointed to a correspondence between Takeda and previous partner Upjohn Co. in 1993, in which Upjohn reportedly told Takeda it was backing out of Actos’ development due to side effect concerns. Takeda allegedly asked Upjohn to change its reason to concerns over the drug’s efficacy, instead of health concerns.
Actos has since been linked to an increased risk of bladder cancer among patients who use the drug for more than 1 year. Studies showed that patients are as much as 40% more likely to develop bladder cancer while taking Actos than alternative type 2 diabetes medications.